...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: The investing worlds' assessment on RVX!

We really need to make some progress with BoM2, and/or Covid developments, showing potential for revenues. The BTD and safety profiles are nice, but don't represent revenues/income anytime in the immediate future.

Some legit Covid advancement, and a good BoM2 interim analysis (assuming we can fund it one way or another), and we are probably looking at a pps projection of $10-30, depending on quality of those items, and market applicability.

So, we wait, again (1-2 years probably?) ... further derisking, getting closer to commercialization & revenues, becoming a viable commercial company/partner, or "swooped" along the way as things progress?! ... are we a viable company with viable products and markets? ... we still don't know yet, difficult to assign favorable future values without more "real" validation instead of just research/theories/potential. Our study history doesn't help our current or projected value, but it does help future development and hopefully honing in on the viable sweet spots.

RVX seems to be opening academic eyes to epigenetics, just need to further validate a "realistic" product applicatioon profile and real commercial potential, rather than just being a research company for the future of epigentics. For many of "us" this has been going on forever, but epigenetics is still just in the very early stage beginnings of the frontier in the circles we need to take notice in a serious way.

There are a lot of promising phase-3 companies that never make it to commercialization for one reason or another, and the smart business people know these risks. Vast potential, but no "meat" ... yet ... the sooner we can get BoM2 going the better.

jmho glta

Share
New Message
Please login to post a reply